NO20055512L - Terapi eller prevensjon av respiratoriske, virale infeksjoner med alfa-tyimosinpeptider - Google Patents

Terapi eller prevensjon av respiratoriske, virale infeksjoner med alfa-tyimosinpeptider

Info

Publication number
NO20055512L
NO20055512L NO20055512A NO20055512A NO20055512L NO 20055512 L NO20055512 L NO 20055512L NO 20055512 A NO20055512 A NO 20055512A NO 20055512 A NO20055512 A NO 20055512A NO 20055512 L NO20055512 L NO 20055512L
Authority
NO
Norway
Prior art keywords
alpha
therapy
prevention
viral infections
respiratory viral
Prior art date
Application number
NO20055512A
Other languages
English (en)
Inventor
Alfred R Rudolph
Cynthia W Tuthill
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Publication of NO20055512L publication Critical patent/NO20055512L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Et alfa-tymosinpeptid kan administreres til en pasient som har eller løper risiko for en respiratorisk, viral infeksjon, koronavirusinfeksjon og/eller SÅRS.
NO20055512A 2003-04-23 2005-11-22 Terapi eller prevensjon av respiratoriske, virale infeksjoner med alfa-tyimosinpeptider NO20055512L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46464503P 2003-04-23 2003-04-23
US47042003P 2003-05-15 2003-05-15
PCT/US2004/012663 WO2004094991A2 (en) 2003-04-23 2004-04-23 Treatment or prevention of respiratory viral infections with alpha thymosin peptides

Publications (1)

Publication Number Publication Date
NO20055512L true NO20055512L (no) 2005-11-22

Family

ID=33313489

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055512A NO20055512L (no) 2003-04-23 2005-11-22 Terapi eller prevensjon av respiratoriske, virale infeksjoner med alfa-tyimosinpeptider

Country Status (12)

Country Link
US (1) US20070036744A1 (no)
EP (1) EP1635854A4 (no)
JP (1) JP2006524704A (no)
KR (1) KR20060013515A (no)
AU (1) AU2004232847B2 (no)
BR (1) BRPI0409711A (no)
CA (1) CA2522891A1 (no)
EA (1) EA009945B1 (no)
MX (1) MXPA05011304A (no)
NO (1) NO20055512L (no)
NZ (1) NZ543651A (no)
WO (1) WO2004094991A2 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
US8337828B2 (en) 2006-05-02 2012-12-25 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of thymosin alpha 1, alone or in combination with PTX3 or ganciclovir, for the treatment of cytomegalovirus infection
EP2344199A1 (en) * 2008-09-19 2011-07-20 Nektar Therapeutics Polymer conjugates of thymosin alpha 1 peptides
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
WO2010129947A2 (en) * 2009-05-08 2010-11-11 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
CA2826875A1 (en) * 2011-02-09 2012-08-16 Sciclone Pharmaceuticals, Inc. Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
CN111671886B (zh) * 2020-03-05 2022-11-15 上海甘翼生物医药科技有限公司 一种预防高危易感人群感染冠状病毒或发生冠状病毒感染疾病的药物组合及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3100974A1 (de) * 1980-01-18 1982-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente enthaltende arzneimittel mit immunregulierender wirkung, und thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente
US4612365A (en) * 1980-03-25 1986-09-16 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften Medicaments containing alpha 1-thymosin and having an immuno regulatory action and alpha 1-thymosin fragments
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy

Also Published As

Publication number Publication date
WO2004094991A3 (en) 2004-12-16
JP2006524704A (ja) 2006-11-02
US20070036744A1 (en) 2007-02-15
EP1635854A4 (en) 2009-08-12
CA2522891A1 (en) 2004-11-04
MXPA05011304A (es) 2005-12-12
EP1635854A2 (en) 2006-03-22
EA200501569A1 (ru) 2006-06-30
AU2004232847A1 (en) 2004-11-04
AU2004232847B2 (en) 2008-11-20
KR20060013515A (ko) 2006-02-10
NZ543651A (en) 2007-01-26
EA009945B1 (ru) 2008-04-28
WO2004094991A2 (en) 2004-11-04
BRPI0409711A (pt) 2006-05-02

Similar Documents

Publication Publication Date Title
Jensen et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort: 45
NO20055512L (no) Terapi eller prevensjon av respiratoriske, virale infeksjoner med alfa-tyimosinpeptider
NO20030337L (no) Anvendelse av hydroksyetylrutosider i fremstilling av medikamenter til behandling av vanlig forkjolelse, virus- og/eller bakterieinfeksjon i luftveiene og/eller oyne, rhinitt og hoyfeber
ATE476983T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen der atemwege
TW200733953A (en) Materials and methods for treating viral infections
WO2008024843A3 (en) Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein
ATE475423T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
NO20073632L (no) Behandling av hepatitt C med interferon-beta i en asiatisk populasjon
WO2006050489A3 (en) Methods of entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions
NO20052420L (no) Farmakologisk behandling av sovnapn±.
WO2007057763A3 (en) Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant
NO20073900L (no) Anvendelse av LGG for fremstilling av et medikament for forebygging eller behandling av respiratoriske sykdommer
AR045870A1 (es) Terapia de combinacion para la infeccion de virus de hepatitis c
NO20064964L (no) Behandling av svekket respiratorisk funksjon
MX2012004409A (es) Proteina recombinante de humano cc10 para el tratamiento de la influenza.
ATE486634T1 (de) Caspase 3, 8, 9 oder 10 inhibitoren in kombination mit mek inhibitoren zur behandlung von influenza
ATE401392T1 (de) Subtypabgestimmte inaktivierte vollvirusvakzine zur behandlung von patienten mit hiv-infektion
TW200501935A (en) Use of resveratrol for preparation of a medicament useful for the treatment of influenza virus infections
DE602005016552D1 (de) Parapocken-viren in kombination mit anderen antiviralen mitteln zur behandlung von hiv/aids
NO20065518L (no) Behandling eller forebyggelse av respiratoriske virusinfeksjoner med immunmodulerende forbindelser.
NO20055243L (no) Interferon beta ved alvorlig akutt respiratorisk syndrom (SARS)
MD20060037A (ro) Metodă de tratament al hepatitei virale acute C
DK1732551T3 (da) Perhexilin til behandling af kronisk hjertesvigt
WO2009023356A3 (en) Materials and methods for treating influenza infections
WO2005058248A3 (en) A method of treating hiv infection in atazanavir resistant patients using a combination of atazanavir and another protease inhibitor

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application